1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Anti-Epileptic Drugs for Pediatrics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Anti-Epileptic Drugs for Pediatrics Market Revenue and Volume, by Drug Generation
8.1.1 First-Generation Anti-Epileptic Drugs
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Second-Generation Anti-Epileptic Drugs
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Third-Generation/Novel AEDs
8.1.3.1. Market Revenue and Volume Forecast
9.1. Anti-Epileptic Drugs for Pediatrics Market Revenue and Volume, by Drug Type
9.1.1. Broad-Spectrum Anti-Epileptic Drugs
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Narrow-Spectrum Anti-Epileptic Drugs
9.1.2.1. Market Revenue and Volume Forecast
10.1. Anti-Epileptic Drugs for Pediatrics Market Revenue and Volume, by End User
10.1.1. Hospitals & Specialty Neurology Clinics
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Pediatric Care Centers
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Ambulatory Surgical Centers
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Other Healthcare Facilities
10.1.4.1. Market Revenue and Volume Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Drug Generation
11.1.2. Market Revenue and Volume Forecast, by Drug Type
11.1.3. Market Revenue and Volume Forecast, by End User
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Drug Generation
11.1.4.2. Market Revenue and Volume Forecast, by Drug Type
11.1.4.3. Market Revenue and Volume Forecast, by End User
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Drug Generation
11.1.5.2. Market Revenue and Volume Forecast, by Drug Type
11.1.5.3. Market Revenue and Volume Forecast, by End User
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Drug Generation
11.2.2. Market Revenue and Volume Forecast, by Drug Type
11.2.3. Market Revenue and Volume Forecast, by End User
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Drug Generation
11.2.4.2. Market Revenue and Volume Forecast, by Drug Type
11.2.4.3. Market Revenue and Volume Forecast, by End User
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Drug Generation
11.2.5.2. Market Revenue and Volume Forecast, by Drug Type
11.2.5.3. Market Revenue and Volume Forecast, by End User
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Drug Generation
11.2.6.2. Market Revenue and Volume Forecast, by Drug Type
11.2.6.3. Market Revenue and Volume Forecast, by End User
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Drug Generation
11.2.7.2. Market Revenue and Volume Forecast, by Drug Type
11.2.7.3. Market Revenue and Volume Forecast, by End User
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Drug Generation
11.3.2. Market Revenue and Volume Forecast, by Drug Type
11.3.3. Market Revenue and Volume Forecast, by End User
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Drug Generation
11.3.4.2. Market Revenue and Volume Forecast, by Drug Type
11.3.4.3. Market Revenue and Volume Forecast, by End User
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Drug Generation
11.3.5.2. Market Revenue and Volume Forecast, by Drug Type
11.3.5.3. Market Revenue and Volume Forecast, by End User
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Drug Generation
11.3.6.2. Market Revenue and Volume Forecast, by Drug Type
11.3.6.3. Market Revenue and Volume Forecast, by End User
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Drug Generation
11.3.7.2. Market Revenue and Volume Forecast, by Drug Type
11.3.7.3. Market Revenue and Volume Forecast, by End User
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Drug Generation
11.4.2. Market Revenue and Volume Forecast, by Drug Type
11.4.3. Market Revenue and Volume Forecast, by End User
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Drug Generation
11.4.4.2. Market Revenue and Volume Forecast, by Drug Type
11.4.4.3. Market Revenue and Volume Forecast, by End User
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Drug Generation
11.4.5.2. Market Revenue and Volume Forecast, by Drug Type
11.4.5.3. Market Revenue and Volume Forecast, by End User
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Drug Generation
11.4.6.2. Market Revenue and Volume Forecast, by Drug Type
11.4.6.3. Market Revenue and Volume Forecast, by End User
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Drug Generation
11.4.7.2. Market Revenue and Volume Forecast, by Drug Type
11.4.7.3. Market Revenue and Volume Forecast, by End User
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Drug Generation
11.5.2. Market Revenue and Volume Forecast, by Drug Type
11.5.3. Market Revenue and Volume Forecast, by End User
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Drug Generation
11.5.4.2. Market Revenue and Volume Forecast, by Drug Type
11.5.4.3. Market Revenue and Volume Forecast, by End User
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Drug Generation
11.5.5.2. Market Revenue and Volume Forecast, by Drug Type
11.5.5.3. Market Revenue and Volume Forecast, by End User
12.1. Marinus Pharmaceuticals, Inc..
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. GW Pharmaceuticals Jazz Pharmaceuticals plc
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eisai Co., Ltd.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Sanofi
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. GlaxoSmithKline plc (GSK)
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Abbott Laboratories
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Teva Pharmaceutical Industries Ltd.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bausch Health Companies Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Lupin Pharmaceuticals
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Sun Pharmaceutical Industries Ltd.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
